• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Darryl Sleep: Identifying and Treating Elevated LDL-C in Patients Can Mitigate Heart Attack Risk

Video

Identifying elevated LDL-C levels in patients and treating them with evolocumab can potentially mitigate and reduce the rate of ischemic events, said Darryl Sleep, MD, senior vice president, global medical and chief medical officer at Amgen.

Identifying elevated LDL-C levels in patients and treating them with evolocumab can potentially mitigate and reduce the rate of ischemic events, said Darryl Sleep, MD, senior vice president for global medical and chief medical officer at Amgen.

Transcript

Can you discuss the significance of the evolocumab FOURIER clinical trial findings and their impact on patients in lowering high LDL-C and subsequent risk of myocardial infarction?

Patients post-myocardial infarction are at significant risk for developing additional ischemic heart disease or myocardial infarction. This is 1 of those areas where it's been clearly identified as a risk factor, and LDL-C is an easily measured biomarker that clearly demonstrates increased risk as well. So, what we've done in the FOURIER study is really identify in this analysis those patients that have had a recent myocardial infarction within the first year of the infarction with elevated LDL-C that number 1, the closer you are to the index event, the more likely you are to have a subsequent event. Elevated LDL-C clearly puts you at risk for that subsequent event and [through] aggressive treatment of patients with elevated LDL-C in that setting, you can actually mitigate, reduce the events, and the rate of events in those patients. So, perfect interface between identifiable marker in patients at risk, a treatment option that can lower LDL-C significantly, and importantly, that reduces the event that you're seeking to prevent.

Related Videos
ISPOR 2024 Recap
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Screenshot of Angela Jia, MD, PhD, during a video interview
Nancy Dreyer, MPH, PhD, FISE, chief scientific advisor to Picnic Health
Screenshot of Alexander Kutikov, MD, during a video interview
Neil Goldfarb, CEO, Greater Philadelphia Business Coalition on Health
Screenshot of Mary Dunn, MSN, NP-C, OCN, RN, during a video interview
Seth Berkowitz, MD, MPH, associate professor of medicine, University of North Carolina at Chapel Hill
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.